Lumida
/ALX
⌘K
Alexander's Inc

Alexander's Inc

ALX
$249.18USD-1.63%-4.12 today

MARKET CAP

1.3B

P/E (TTM)

62.1x

FWD P/E

DAY RANGE

$246 – $255

52W RANGE

$201
$289

AI Summary

Stalk
TrimMedium

ALX remains under pressure following a decisive support failure, trading below short‐term EMAs and approaching the rising 200-day SMA. Despite extreme oversold conditions, the medium-term bias is bearish, so bearish execution should be deferred until a relief bounce into the 261–266 zone where EMAs now act as resistance. Long-term trend stays intact as long as price holds above the 200-day SMA.

  • Evorpacept and ALX2004 trials tracking for registrational studies by mid-2027.
  • Earnings yield ~22% indicates resource efficiency and possible undervaluation.
  • Weak balance sheet quality raises funding concerns for ongoing trials.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$206.1M$205.8M$225.0M$226.4M$213.2M
YoY %+3.5%-0.2%+9.3%+0.6%-5.8%
P / Sales6.5x5.5x4.9x4.5x5.2x
EV / Sales9.7x10.2x7.7x8.2x9.3x
Gross Profit, Adj.$206.1M$205.8M$225.0M$226.4M$213.2M
YoY %+3.5%-0.2%+9.3%+0.6%-5.8%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit9.7x10.2x7.7x8.2x9.3x
EBITDA, Adj.$110.8M$110.9M$119.1M$124.6M$110.7M
YoY %+3.4%+0.1%+7.4%+4.6%-11.2%
Margin %53.7%53.9%53.0%55.1%51.9%
EV / EBITDA18.1x19.0x14.6x14.9x18.0x
EBIT$76.2M$79.5M$84.5M$81.8M$65.2M
YoY %+5.7%+4.3%+6.4%-3.2%-20.3%
Margin %37.0%38.6%37.6%36.1%30.6%
EV / EBIT26.4x26.5x20.6x22.6x30.6x
Net Income$132.9M$57.6M$102.4M$43.4M$28.2M
YoY %+217.0%-56.6%+77.7%-57.6%-35.0%
Net Margin64.5%28.0%45.5%19.2%13.2%
EPS (GAAP)$25.94$11.24$19.97$8.46$5.50
YoY %+216.7%-56.7%+77.7%-57.6%-35.0%